{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:46:47Z","timestamp":1775850407197,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A19694"],"award-info":[{"award-number":["C41405\/A19694"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A13034"],"award-info":[{"award-number":["C41405\/A13034"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A19694"],"award-info":[{"award-number":["C41405\/A19694"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A19694"],"award-info":[{"award-number":["C41405\/A19694"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A19694"],"award-info":[{"award-number":["C41405\/A19694"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C41405\/A13034"],"award-info":[{"award-number":["C41405\/A13034"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C16420\/A18066"],"award-info":[{"award-number":["C16420\/A18066"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C355\/A25137"],"award-info":[{"award-number":["C355\/A25137"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oncolytic viruses are being tested in clinical trials, including in women with ovarian cancer. We use a drug-repurposing approach to identify existing drugs that enhance the activity of oncolytic adenoviruses. This reveals that carvedilol, a \u03b2-arrestin-biased \u03b2-blocker, synergises with both wild-type adenovirus and the E1A-CR2-deleted oncolytic adenovirus, <jats:italic>dl<\/jats:italic>922-947. Synergy is not due to \u03b2-adrenergic blockade but is dependent on \u03b2-arrestins and is reversed by \u03b2-arrestin CRISPR gene editing. Co-treatment with <jats:italic>dl<\/jats:italic>922-947 and carvedilol causes increased viral DNA replication, greater viral protein expression and higher titres of infectious viral particles. Carvedilol also enhances viral efficacy in orthotopic, intraperitoneal murine models, achieving more rapid tumour clearance than virus alone. Increased anti-cancer activity is associated with an intratumoural inflammatory cell infiltrate and systemic cytokine release. In summary, carvedilol augments the activity of oncolytic adenoviruses via \u03b2-arrestins to re-wire cytokine networks and innate immunity and could therefore improve oncolytic viruses for cancer patient treatment.<\/jats:p>","DOI":"10.1038\/s42003-022-03041-4","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:05:49Z","timestamp":1643886349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Carvedilol targets \u03b2-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy"],"prefix":"10.1038","volume":"5","author":[{"given":"Joseph I.","family":"Hoare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bleona","family":"Osmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayeta","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-6601","authenticated-orcid":false,"given":"Sarah A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9281-5789","authenticated-orcid":false,"given":"Michelle","family":"Lockley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"3041_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359\u2013E386 (2015).","journal-title":"Int J Cancer"},{"key":"3041_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ygyno.2016.10.019","volume":"144","author":"M Matz","year":"2017","unstructured":"Matz, M. et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol 144, 405\u2013413 (2017).","journal-title":"Gynecol Oncol"},{"key":"3041_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15, 668\u2013679 (2015).","journal-title":"Nat Rev Cancer"},{"key":"3041_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","volume":"21","author":"A Rosewell Shaw","year":"2016","unstructured":"Rosewell Shaw, A. & Suzuki, M. Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol 21, 9\u201315 (2016).","journal-title":"Curr Opin Virol"},{"key":"3041_CR5","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1002\/jcp.27850","volume":"234","author":"NH Goradel","year":"2019","unstructured":"Goradel, N. H. et al. Oncolytic adenovirus: a tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol 234, 8636\u20138646 (2019).","journal-title":"J Cell Physiol"},{"key":"3041_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki, T. et al. Phase I study with ONCOS-102 for the treatment of solid tumors\u2014an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer 4, 17 (2016).","journal-title":"J Immunother Cancer"},{"key":"3041_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","volume":"23","author":"X Li","year":"2017","unstructured":"Li, X. et al. The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in Syrian hamster model. Clin Cancer Res 23, 239\u2013249 (2017).","journal-title":"Clin Cancer Res"},{"key":"3041_CR8","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","volume":"24","author":"H Uusi-Kerttula","year":"2018","unstructured":"Uusi-Kerttula, H. et al. Ad5NULL-A20: a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res 24, 4215\u20134224 (2018).","journal-title":"Clin Cancer Res"},{"key":"3041_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/1878-0261.12628","volume":"14","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. A SIRPalpha-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol 14, 657\u2013668 (2020).","journal-title":"Mol Oncol"},{"key":"3041_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/mt.2010.247","volume":"19","author":"MA Salako","year":"2011","unstructured":"Salako, M. A. et al. Inhibition of the inflammatory cytokine TNF-alpha increases adenovirus activity in ovarian cancer via modulation of cIAP1\/2 expression. Mol Ther 19, 490\u2013499 (2011).","journal-title":"Mol Ther"},{"key":"3041_CR11","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/0008-5472.CAN-14-3761","volume":"75","author":"A Browne","year":"2015","unstructured":"Browne, A. et al. Pharmacological inhibition of beta3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Res 75, 2811\u20132821 (2015).","journal-title":"Cancer Res"},{"key":"3041_CR12","doi-asserted-by":"publisher","first-page":"26328","DOI":"10.18632\/oncotarget.25242","volume":"9","author":"SL Hulin-Curtis","year":"2018","unstructured":"Hulin-Curtis, S. L. et al. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9, 26328\u201326341 (2018).","journal-title":"Oncotarget"},{"key":"3041_CR13","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.pbj.0000000000000007","volume":"3","author":"J Hoare","year":"2018","unstructured":"Hoare, J., Campbell, N. & Carapuca, E. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses. Porto Biomed J 3, e7 (2018).","journal-title":"Porto Biomed J"},{"key":"3041_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ygyno.2020.02.034","volume":"157","author":"RC Arend","year":"2020","unstructured":"Arend, R. C. et al. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I\/II study are associated with an immunotherapeutic effect. Gynecol Oncol 157, 578\u2013584 (2020).","journal-title":"Gynecol Oncol"},{"key":"3041_CR15","unstructured":"Clinicaltrials.gov. GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02759588 (2016)."},{"key":"3041_CR16","unstructured":"Clinicaltrials.gov. MV-NIS or Investigator\u2019s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02364713 (2015)."},{"key":"3041_CR17","unstructured":"Clinicaltrials.gov. A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03398655 (2018)."},{"key":"3041_CR18","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33, 2780\u20132788 (2015).","journal-title":"J Clin Oncol"},{"key":"3041_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6, 1134\u20131139 (2000).","journal-title":"Nat Med"},{"key":"3041_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","volume":"2","author":"CJ Sherr","year":"2002","unstructured":"Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103\u2013112 (2002).","journal-title":"Cancer Cell"},{"key":"3041_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/0008-5472.CAN-05-2691","volume":"66","author":"M Lockley","year":"2006","unstructured":"Lockley, M. et al. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 66, 989\u2013998 (2006).","journal-title":"Cancer Res"},{"key":"3041_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1541-7786.MCR-15-0188-T","volume":"14","author":"LA Tookman","year":"2016","unstructured":"Tookman, L. A. et al. RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer. Mol Cancer Res 14, 44\u201355 (2016).","journal-title":"Mol Cancer Res"},{"key":"3041_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1172\/JCI43976","volume":"121","author":"CM Connell","year":"2011","unstructured":"Connell, C. M. et al. Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. J Clin Invest 121, 1283\u20131297 (2011).","journal-title":"J Clin Invest"},{"key":"3041_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.molonc.2014.12.007","volume":"9","author":"CK Ingemarsdotter","year":"2015","unstructured":"Ingemarsdotter, C. K. et al. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol 9, 791\u2013805 (2015).","journal-title":"Mol Oncol"},{"key":"3041_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01855-z","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Galphai is required for carvedilol-induced beta1 adrenergic receptor beta-arrestin biased signaling. Nat Commun 8, 1706 (2017).","journal-title":"Nat Commun"},{"key":"3041_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/pr.116.013367","volume":"69","author":"YK Peterson","year":"2017","unstructured":"Peterson, Y. K. & Luttrell, L. M. The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev 69, 256\u2013297 (2017).","journal-title":"Pharmacol Rev"},{"key":"3041_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.healun.2006.01.008","volume":"25","author":"J Park","year":"2006","unstructured":"Park, J. et al. Carvedilol inhibits platelet-derived growth factor-induced extracellular matrix synthesis by inhibiting cellular reactive oxygen species and mitogen-activated protein kinase activation. J Heart Lung Transplant 25, 683\u2013689 (2006).","journal-title":"J Heart Lung Transplant"},{"key":"3041_CR28","first-page":"189","volume":"52","author":"RF De Araujo Jr.","year":"2018","unstructured":"De Araujo, R. F. Jr. et al. Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK\/Akt\/mTOR pathway and EGFR\/FAAD proteins. Int J Oncol 52, 189\u2013200 (2018).","journal-title":"Int J Oncol"},{"key":"3041_CR29","doi-asserted-by":"publisher","first-page":"1874762","DOI":"10.1155\/2016\/1874762","volume":"2016","author":"NA El-Shitany","year":"2016","unstructured":"El-Shitany, N. A. & El-Desoky, K. Protective effects of carvedilol and vitamin C against azithromycin-induced cardiotoxicity in rats via decreasing ROS, IL1-beta, and TNF-alpha production and inhibiting NF-kappaB and caspase-3 expression. Oxid Med Cell Longev 2016, 1874762 (2016).","journal-title":"Oxid Med Cell Longev"},{"key":"3041_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0008-6363(03)00459-0","volume":"59","author":"SP Yang","year":"2003","unstructured":"Yang, S. P. et al. Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc Res 59, 776\u2013787 (2003).","journal-title":"Cardiovasc Res"},{"key":"3041_CR31","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.3802\/jgo.2018.29.e82","volume":"29","author":"MH Baek","year":"2018","unstructured":"Baek, M. H., Kim, D. Y., Kim, S. O., Kim, Y. J. & Park, Y. H. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study. J Gynecol Oncol 29, e82 (2018).","journal-title":"J Gynecol Oncol"},{"key":"3041_CR32","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1002\/cncr.29392","volume":"121","author":"JL Watkins","year":"2015","unstructured":"Watkins, J. L. et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian. Cancer 121, 3444\u20133451 (2015).","journal-title":"Cancer"},{"key":"3041_CR33","doi-asserted-by":"publisher","first-page":"16657","DOI":"10.1073\/pnas.0707936104","volume":"104","author":"JW Wisler","year":"2007","unstructured":"Wisler, J. W. et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104, 16657\u201316662 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"3041_CR34","unstructured":"Chou, T. et al. ComboSyn Inc Paramus NJ. (2005)."},{"key":"3041_CR35","doi-asserted-by":"publisher","first-page":"14555","DOI":"10.1073\/pnas.0804745105","volume":"105","author":"IM Kim","year":"2008","unstructured":"Kim, I. M. et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105, 14555\u201314560 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"3041_CR36","doi-asserted-by":"publisher","first-page":"155394","DOI":"10.1016\/j.cyto.2020.155394","volume":"138","author":"K Amirshahrokhi","year":"2021","unstructured":"Amirshahrokhi, K. & Zohouri, A. Carvedilol prevents pancreatic beta-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-kappaB, COX-2, iNOS and oxidative stress. Cytokine 138, 155394 (2021).","journal-title":"Cytokine"},{"key":"3041_CR37","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1073\/pnas.0402851101","volume":"101","author":"DS Witherow","year":"2004","unstructured":"Witherow, D. S., Garrison, T. R., Miller, W. E. & Lefkowitz, R. J. beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci USA 101, 8603\u20138607 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"3041_CR38","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1016\/j.molimm.2007.02.009","volume":"44","author":"H Fan","year":"2007","unstructured":"Fan, H. et al. Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol Immunol 44, 3092\u20133099 (2007).","journal-title":"Mol Immunol"},{"key":"3041_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/01.fjc.0000201359.58174.c8","volume":"47","author":"H Fujio","year":"2006","unstructured":"Fujio, H. et al. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 47, 250\u2013255 (2006).","journal-title":"J Cardiovasc Pharmacol"},{"key":"3041_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo_00000563","volume":"36","author":"M Erguven","year":"2010","unstructured":"Erguven, M. et al. Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36, 857\u2013866 (2010).","journal-title":"Int J Oncol"},{"key":"3041_CR41","doi-asserted-by":"publisher","first-page":"e0217038","DOI":"10.1371\/journal.pone.0217038","volume":"14","author":"KH Cleveland","year":"2019","unstructured":"Cleveland, K. H. et al. Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors. PLoS One 14, e0217038 (2019).","journal-title":"PLoS One"},{"key":"3041_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","volume":"7","author":"AJR McGray","year":"2019","unstructured":"McGray, A. J. R. et al. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. J Immunother Cancer 7, 189 (2019).","journal-title":"J Immunother Cancer"},{"key":"3041_CR43","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1021\/acs.jproteome.9b00173","volume":"18","author":"JP Murphy","year":"2019","unstructured":"Murphy, J. P. et al. Therapy-induced MHC I ligands shape neo-antitumor CD8 T cell responses during oncolytic virus-based cancer immunotherapy. J Proteome Res 18, 2666\u20132675 (2019).","journal-title":"J Proteome Res"},{"key":"3041_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0282-3","volume":"9","author":"ED Thomas","year":"2016","unstructured":"Thomas, E. D. et al. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. J Ovarian Res 9, 70 (2016).","journal-title":"J Ovarian Res"},{"key":"3041_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1023\/A:1011338119712","volume":"6","author":"AW Braithwaite","year":"2001","unstructured":"Braithwaite, A. W. & Russell, I. A. Induction of cell death by adenoviruses. Apoptosis 6, 359\u2013370 (2001).","journal-title":"Apoptosis"},{"key":"3041_CR46","first-page":"333","volume":"67","author":"H Tazawa","year":"2013","unstructured":"Tazawa, H., Kagawa, S. & Fujiwara, T. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Acta Med Okayama 67, 333\u2013342 (2013).","journal-title":"Acta Med Okayama"},{"key":"3041_CR47","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1038\/sj.onc.1210977","volume":"27","author":"SK Baird","year":"2008","unstructured":"Baird, S. K. et al. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27, 3081\u20133090 (2008).","journal-title":"Oncogene"},{"key":"3041_CR48","doi-asserted-by":"publisher","unstructured":"Tazawa, H., Kuroda, S., Hasei, J., Kagawa, S. & Fujiwara, T. Impact of autophagy in oncolytic adenoviral therapy for cancer. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms18071479 (2017).","DOI":"10.3390\/ijms18071479"},{"key":"3041_CR49","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/cddiscovery.2016.76","volume":"2","author":"JR Radke","year":"2016","unstructured":"Radke, J. R., Siddiqui, Z. K., Figueroa, I. & Cook, J. L. E1A enhances cellular sensitivity to DNA-damage-induced apoptosis through PIDD-dependent caspase-2 activation. Cell Death Discov 2, 16076 (2016).","journal-title":"Cell Death Discov"},{"key":"3041_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13323","volume":"163","author":"A Teijeira Crespo","year":"2021","unstructured":"Teijeira Crespo, A. et al. Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163, 389\u2013398 (2021).","journal-title":"Immunology"},{"key":"3041_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","volume":"39","author":"E Ramelyte","year":"2021","unstructured":"Ramelyte, E. et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell 39, 394\u2013406 e394 (2021).","journal-title":"Cancer Cell"},{"key":"3041_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1525-0016(03)00199-0","volume":"8","author":"G Hallden","year":"2003","unstructured":"Hallden, G. et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 8, 412\u2013424 (2003).","journal-title":"Mol Ther"},{"key":"3041_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12794-2","volume":"10","author":"H Huang","year":"2019","unstructured":"Huang, H. et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat Commun 10, 4801 (2019).","journal-title":"Nat Commun"},{"key":"3041_CR54","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi, G. et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances Anti-PD-1 immunotherapy. Mol Ther 27, 244\u2013260 (2019).","journal-title":"Mol Ther"},{"key":"3041_CR55","doi-asserted-by":"publisher","first-page":"706517","DOI":"10.3389\/fimmu.2021.706517","volume":"12","author":"V Cervera-Carrascon","year":"2021","unstructured":"Cervera-Carrascon, V. et al. Adenovirus armed with TNFa and IL2 Added to aPD-1 regimen mediates antitumor efficacy in tumors refractory to aPD-1. Front Immunol 12, 706517 (2021).","journal-title":"Front Immunol"},{"key":"3041_CR56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1124\/jpet.115.225375","volume":"355","author":"YL Chen","year":"2015","unstructured":"Chen, Y. L. et al. Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. J Pharmacol Exp Ther 355, 516\u2013527 (2015).","journal-title":"J Pharmacol Exp Ther"},{"key":"3041_CR57","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3389\/fonc.2020.01696","volume":"10","author":"H Tian","year":"2020","unstructured":"Tian, H., Lyu, Y., Yang, Y. G. & Hu, Z. Humanized rodent models for cancer research. Front Oncol 10, 1696 (2020).","journal-title":"Front Oncol"},{"key":"3041_CR58","first-page":"4568","volume":"10","author":"L Yin","year":"2020","unstructured":"Yin, L., Wang, X. J., Chen, D. X., Liu, X. N. & Wang, X. J. Humanized mouse model: a review on preclinical applications for cancer immunotherapy. Am J Cancer Res 10, 4568\u20134584 (2020).","journal-title":"Am J Cancer Res"},{"key":"3041_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature Communications 4, 2126 (2013).","journal-title":"Nature Communications"},{"key":"3041_CR60","doi-asserted-by":"publisher","unstructured":"Hoare, J. I. et al. Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer. bioRxiv https:\/\/doi.org\/10.1101\/2020.07.23.200378 (2020).","DOI":"10.1101\/2020.07.23.200378"},{"key":"3041_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/emmm.200900040","volume":"1","author":"SA Martin","year":"2009","unstructured":"Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO molecular medicine 1, 323\u2013337 (2009).","journal-title":"EMBO molecular medicine"},{"key":"3041_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03665-0","volume":"12","author":"VL Silva","year":"2021","unstructured":"Silva, V. L. et al. Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer. Cell Death Dis 12, 395 (2021).","journal-title":"Cell Death Dis"},{"key":"3041_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints12. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"3041_CR64","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1258\/ebm.2012.012022","volume":"237","author":"K Shimada","year":"2012","unstructured":"Shimada, K., Hirano, E., Kimura, T., Fujita, M. & Kishimoto, C. Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production. Exp Biol Med (Maywood) 237, 1039\u20131044 (2012).","journal-title":"Exp Biol Med (Maywood)"},{"key":"3041_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.gene.2014.06.003","volume":"547","author":"D Wang","year":"2014","unstructured":"Wang, D. et al. Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene 547, 195\u2013201 (2014).","journal-title":"Gene"},{"key":"3041_CR66","doi-asserted-by":"publisher","unstructured":"Lockley, M. & Hoare, J. Carvedilol targets \u03b2-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy. figshare https:\/\/doi.org\/10.6084\/m9.figshare.17013317.v1 (2021).","DOI":"10.6084\/m9.figshare.17013317.v1"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03041-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03041-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:02:10Z","timestamp":1669363330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03041-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03041-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}